Skip to search formSkip to main contentSkip to account menu

10 ML nivolumab 10 MG/ML Injection [Opdivo]

Known as: NIVOLUMAB 10 mg in 1 mL INTRAVENOUS INJECTION [OPDIVO], Opdivo 100 MG in 10 ML Injection, Opdivo 100 MG per 10 ML Injection 
National Institutes of Health

Related topics

Related topics

10 relations
Hydrochloric AcidInjectionMannitolPentetic Acid

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Nivolumab vs investigator ’ s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck : Efficacy and safety in CheckMate 141 by prior cetuximab use
  • 2019
  • Corpus ID: 157059814
104 Clinical Science Symposium: "Check" This Out: The Step Beyond PD-1 Blockade Sunday, June 4, 10:12–10:24 AM, Hall D1 Clinical… 
2018
2018
Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with advanced RCC
Renal cell carcinomas (RCCs) arise from the renal cortex; many patients with RCC are asymptomatic until the disease is either… 
2017
2017
First Patient Dosed in a Phase 1 / 2 Trial of Pexa-Vec + Opdivo ® for the First-Line Treatment of Advanced Liver Cancer
  • 2017
  • Corpus ID: 166220677
Strasbourg, France, July 31, 2017, 5:45 p.m. CET Transgene (Euronext Paris: TNG), a company that designs and develops viral-based… 
2017
2017
Measuring Markers of Immune Response in Patients Treated with Nivolumab (Opdivo®) and Pembrolizumab (Keytruda®)
2017
2017
Abstract 663: Clinical performance and utilization of 3 PD-L1 immunohistochemical assays
Three different PD-L1 immunohistochemical (IHC) assays have recently been approved to help guide treatment decisions regarding… 
2017
2017
Nivolumab (Opdivo°) and metastatic or inoperable lung cancer.
  • Prescrire international
  • 2017
  • Corpus ID: 73417016
2016
2016
Companion and complementary diagnostics for PD-L1 expression assessment in non-small cell lung cancer.
11612Background: Recently two different immunohistochemical assays for PD-L1 expression in non-small cell lung cancers have been… 
2016
2016
Immunothérapie des cancers : rationnel et avancées récentes
Review
2016
Review
2016
Nivolumab for Metastatic Melanoma.
Melanoma is an aggressive skin cancer with a generally poor prognosis at Stage III-IV disease. Traditionally, metastatic melanoma… 
2015
2015
Nivolumab (Opdivo®) as single-agent first-line therapy for unresectable or metastatic melanoma
Nivolumab is a fully human IgG4 monoclonal antibody that blocks the binding of the programmed cell death receptor-1 protein (PD-1… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)